Martenyi 2001.

Methods	Six‐week randomised, double‐blind, four‐centre study
Participants	Inpatients fulfilling DSM‐III‐R criteria for non‐psychotic major depression, with a score of at least 18 on the Hamilton Rating Scale for Depression‐17 item (HDRS‐17). Age range: 18‐65 years Exclusion criteria: history of any psychoactive disorder, bipolar mood disorder, substance abuse disorder, somatic disorder, glaucoma, urinary retention and/or prostatic disease and known allergy to maprotiline, pregnancy, absence of contraception, use of MAOI within 2 weeks and depot neuroleptics within 4 weeks of study entry, concomitant psychotropic active medication, with the exception of midazolam, max 15 mg, or medazepam, max 5 mg, for insomnia.
Interventions	Fluoxetine: 59 participants Maprotiline : 46 participants Fluoxetine dose: 20 mg/day Maprotiline dose range: 100‐200 mg/day
Outcomes	HDRS‐17, Clinical Global Impression‐Severity (CGI)
Notes	Funding: by industry
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised, no further information
Allocation concealment (selection bias)	Unclear risk	No information provided
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Double blind, no further information
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Quote: "to maintain the blind, all patients took three capsules of study medication every day", no further information
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Double blind, no further information
Incomplete outcome data (attrition bias) All outcomes	High risk	Number and reasons for discontinuation were not reported. Scores reported without denominator
Selective reporting (reporting bias)	Unclear risk	Endpoint scores reported with standard deviation. Side effects not reported
Other bias	High risk	Quote: "this work was sponsored by Eli Lilly and Company". This company produces fluoxetine